{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:50:25Z","timestamp":1780527025846,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA091842"],"award-info":[{"award-number":["P30 CA091842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The growing interest and clinical translation of alpha particle (\u03b1) therapies brings with it new challenges to assess target cell engagement and to monitor therapeutic effect. Noninvasive imaging has great potential to guide \u03b1-treatment and to harness the potential of these agents in the complex environment of disseminated disease. Poly(ADP) ribose polymerase 1 (PARP-1) is among the most abundantly expressed DNA repair enzymes with key roles in multiple repair pathways\u2014such as those induced by irradiation. Here, we used a third-generation PARP1-specific radiotracer, [\n                    <jats:sup>18<\/jats:sup>\n                    F]-PARPZ, to delineate castrate resistant prostate cancer xenografts. Following treatment with the clinically applied [\n                    <jats:sup>225<\/jats:sup>\n                    Ac]-PSMA-617, positron emission tomography was performed and correlative autoradiography and histology acquired. [\n                    <jats:sup>18<\/jats:sup>\n                    F]-PARPZ was able to distinguish treated from control (saline) xenografts by increased uptake. Kinetic analysis of tracer accumulation also suggests that the localization of the agent to sites of increased PARP-1 expression is a consequence of DNA damage response. Together, these data support expanded investigation of [\n                    <jats:sup>18<\/jats:sup>\n                    F]-PARPZ to facilitate clinical translation in the \u237a-therapy space.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-17460-0","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T07:04:04Z","timestamp":1659078244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["[18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response"],"prefix":"10.1038","volume":"12","author":[{"given":"Hanwen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Abou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbie Meghan","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandria","family":"Villmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Benabdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ulmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Carlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buck E.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman F.","family":"Turtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"McDevitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian W.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrokh","family":"Dehdashti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L. J.","family":"Thorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"17460_CR1","volume-title":"Cancer: Disease Control Priorities","author":"DA Jaffray","year":"2016","unstructured":"Jaffray, D. A. & Gospodarowicz, M. K. Radiation therapy for cancer. In Cancer: Disease Control Priorities 3rd edn, Vol. 3 (eds Gelband, H. et al.) (The International Bank for Reconstruction and Development\/The World Bank, 2016).","edition":"3"},{"key":"17460_CR2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.3389\/fonc.2020.00884","volume":"10","author":"D Abou","year":"2020","unstructured":"Abou, D. et al. Prostate cancer theranostics\u2014An overview. Front. Oncol. 10, 884 (2020).","journal-title":"Front. Oncol."},{"key":"17460_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/3578453","volume":"134","author":"JL Humm","year":"1993","unstructured":"Humm, J. L. & Chin, L. M. A model of cell inactivation by alpha-particle internal emitters. Radiat. Res. 134, 143\u2013150 (1993).","journal-title":"Radiat. Res."},{"key":"17460_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","volume":"20","author":"PG Kluetz","year":"2014","unstructured":"Kluetz, P. G. et al. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 20, 9\u201314 (2014).","journal-title":"Clin. Cancer Res."},{"key":"17460_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213\u2013223 (2013).","journal-title":"N. Engl. J. Med."},{"key":"17460_CR6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil, C. et al. 225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941\u20131944 (2016).","journal-title":"J. Nucl. Med."},{"key":"17460_CR7","first-page":"129","volume":"45","author":"M Miederer","year":"2004","unstructured":"Miederer, M. et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J. Nucl. Med. 45, 129\u2013137 (2004).","journal-title":"J. Nucl. Med."},{"key":"17460_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1097\/COC.0000000000000353","volume":"41","author":"RF Meredith","year":"2018","unstructured":"Meredith, R. F. et al. Safety and outcome measures of first-in-human intraperitoneal \u03b1 radioimmunotherapy with 212Pb-TCMC-trastuzumab. Am. J. Clin. Oncol. 41, 716\u2013721 (2018).","journal-title":"Am. J. Clin. Oncol."},{"key":"17460_CR9","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","volume":"50","author":"H Andersson","year":"2009","unstructured":"Andersson, H. et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of (211)At-MX35 F(ab\u2019)2\u2014A phase I study. J. Nucl. Med. 50, 1153\u20131160 (2009).","journal-title":"J. Nucl. Med."},{"key":"17460_CR10","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/s41467-018-04107-w","volume":"9","author":"MR McDevitt","year":"2018","unstructured":"McDevitt, M. R. et al. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat. Commun. 9, 1629 (2018).","journal-title":"Nat. Commun."},{"key":"17460_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","volume":"79","author":"B Feuerecker","year":"2021","unstructured":"Feuerecker, B. et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA. Eur. Urol. 79, 343\u2013350 (2021).","journal-title":"Eur. Urol."},{"key":"17460_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"MR McDevitt","year":"2001","unstructured":"McDevitt, M. R. et al. Tumor therapy with targeted atomic nanogenerators. Science 294, 1537\u20131540 (2001).","journal-title":"Science"},{"key":"17460_CR13","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","volume":"28","author":"TL Rosenblat","year":"2022","unstructured":"Rosenblat, T. L. et al. Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nano-generator actinium-225-lintuzumab. Clin. Cancer Res. 28, 2030\u20132037 (2022).","journal-title":"Clin. Cancer Res."},{"key":"17460_CR14","first-page":"166","volume":"40","author":"TK Nikula","year":"1999","unstructured":"Nikula, T. K. et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry. J. Nucl. Med. 40, 166\u2013176 (1999).","journal-title":"J. Nucl. Med."},{"key":"17460_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil, C. et al. Targeted \u03b1-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control. J. Nucl. Med. 59, 795\u2013802 (2018).","journal-title":"J. Nucl. Med."},{"key":"17460_CR16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","volume":"76","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho, P. et al. Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects. Eur. Urol. 76, 170\u2013176 (2018).","journal-title":"Eur. Urol."},{"key":"17460_CR17","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2967\/jnumed.118.213223","volume":"60","author":"TC Wilson","year":"2019","unstructured":"Wilson, T. C. et al. PET imaging of PARP expression using 18F-olaparib. J. Nucl. Med. 60, 504\u2013510 (2019).","journal-title":"J. Nucl. Med."},{"key":"17460_CR18","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1158\/0008-5472.CAN-10-4587","volume":"71","author":"B Cornelissen","year":"2011","unstructured":"Cornelissen, B. et al. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res. 71, 4539\u20134549 (2011).","journal-title":"Cancer Res."},{"key":"17460_CR19","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.bmc.2014.01.019","volume":"22","author":"D Zhou","year":"2014","unstructured":"Zhou, D. et al. Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg. Med. Chem. 22, 1700\u20131707 (2014).","journal-title":"Bioorg. Med. Chem."},{"key":"17460_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00259-016-3604-1","volume":"44","author":"JC Knight","year":"2017","unstructured":"Knight, J. C., Koustoulidou, S. & Cornelissen, B. Imaging the DNA damage response with PET and SPECT. Eur. J. Nucl. Med. Mol. Imaging 44, 1065\u20131078 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"17460_CR21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/356356a0","volume":"356","author":"MS Satoh","year":"1992","unstructured":"Satoh, M. S. & Lindahl, T. Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 356\u2013358 (1992).","journal-title":"Nature"},{"key":"17460_CR22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/283593a0","volume":"283","author":"BW Durkacz","year":"1980","unstructured":"Durkacz, B. W., Omidiji, O., Gray, D. A. & Shall, S. (ADP-ribose)n participates in DNA excision repair. Nature 283, 593\u2013596 (1980).","journal-title":"Nature"},{"key":"17460_CR23","first-page":"1","volume-title":"Advances in Radiation Biology","author":"S Shall","year":"1984","unstructured":"Shall, S. ADP-ribose in DNA repair: A new component of DNA excision repair. In Advances in Radiation Biology (ed. Lett, J. T.) 1\u201369 (Elsevier, 1984)."},{"key":"17460_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610\u2013621 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"17460_CR25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1148\/radiol.2016161929","volume":"282","author":"LS Michel","year":"2017","unstructured":"Michel, L. S. et al. PET of poly (ADP-Ribose) polymerase activity in cancer: Preclinical assessment and first in-human studies. Radiology 282, 453\u2013463 (2017).","journal-title":"Radiology"},{"key":"17460_CR26","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1172\/JCI97992","volume":"128","author":"M Makvandi","year":"2018","unstructured":"Makvandi, M. et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J. Clin. Invest. 128, 2116\u20132126 (2018).","journal-title":"J. Clin. Invest."},{"key":"17460_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.nucmedbio.2018.08.003","volume":"66","author":"D Zhou","year":"2018","unstructured":"Zhou, D. et al. Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer. Nucl. Med. Biol. 66, 26\u201331 (2018).","journal-title":"Nucl. Med. Biol."},{"key":"17460_CR28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","volume":"17","author":"Z Szabo","year":"2015","unstructured":"Szabo, Z. et al. Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol. Imaging Biol. 17, 565\u2013574 (2015).","journal-title":"Mol. Imaging Biol."},{"key":"17460_CR29","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.2174\/092986712799462612","volume":"19","author":"CA Foss","year":"2012","unstructured":"Foss, C. A., Mease, R. C., Cho, S. Y., Kim, H. J. & Pomper, M. G. GCPII imaging and cancer. Curr. Med. Chem. 19, 1346\u20131359 (2012).","journal-title":"Curr. Med. Chem."},{"key":"17460_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"17460_CR31","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nature15736","volume":"528","author":"Cancer Cell Line Encyclopedia Consortium, and Genomics of Drug Sensitivity in Cancer Consortium","year":"2015","unstructured":"Cancer Cell Line Encyclopedia Consortium, and Genomics of Drug Sensitivity in Cancer Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84\u201387 (2015).","journal-title":"Nature"},{"key":"17460_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/laban0511-155","volume":"40","author":"T Yardeni","year":"2011","unstructured":"Yardeni, T., Eckhaus, M., Morris, H. D., Huizing, M. & Hoogstraten-Miller, S. Retro-orbital injections in mice. Lab Anim. 40, 155\u2013160 (2011).","journal-title":"Lab Anim."},{"key":"17460_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2018.05.003","volume":"62\u201363","author":"W Jiang","year":"2018","unstructured":"Jiang, W., Ulmert, D., Simons, B. W., Abou, D. S. & Thorek, D. L. J. The impact of age on radium-223 distribution and an evaluation of molecular imaging surrogates. Nucl. Med. Biol. 62\u201363, 1\u20138 (2018).","journal-title":"Nucl. Med. Biol."},{"key":"17460_CR34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jnci\/djv380","volume":"108","author":"DS Abou","year":"2016","unstructured":"Abou, D. S. et al. Whole-body and microenvironmental localization of radium-223 in naive and mouse models of prostate cancer metastasis. J. Natl. Cancer Inst. 108, 380 (2016).","journal-title":"J. Natl. Cancer Inst."},{"key":"17460_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199239","volume":"13","author":"JR Nu\u00f1ez","year":"2018","unstructured":"Nu\u00f1ez, J. R., Anderton, C. R. & Renslow, R. S. Optimizing colormaps with consideration for color vision deficiency to enable accurate interpretation of scientific data. PLoS ONE 13, e0199239 (2018).","journal-title":"PLoS ONE"},{"key":"17460_CR36","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"17460_CR37","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2967\/jnumed.117.205765","volume":"59","author":"S Kossatz","year":"2018","unstructured":"Kossatz, S. et al. Direct imaging of drug distribution and target engagement of the PARP inhibitor rucaparib. J. Nucl. Med. 59, 1316\u20131320 (2018).","journal-title":"J. Nucl. Med."},{"key":"17460_CR38","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1038\/s41598-022-07319-9","volume":"12","author":"A Mateos-Pujante","year":"2022","unstructured":"Mateos-Pujante, A., Jim\u00e9nez, M. C. & Andreu, I. Evaluation of phototoxicity induced by the anticancer drug rucaparib. Sci. Rep. 12, 3434 (2022).","journal-title":"Sci. Rep."},{"key":"17460_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1741-7015-10-25","volume":"10","author":"S Kummar","year":"2012","unstructured":"Kummar, S. et al. Advances in using PARP inhibitors to treat cancer. BMC Med. 10, 25 (2012).","journal-title":"BMC Med."},{"key":"17460_CR40","first-page":"9","volume":"32","author":"S Sander Effron","year":"2017","unstructured":"Sander Effron, S. et al. PARP-1 expression quantified by [18F]FluorThanatrace: A biomarker of response to PARP inhibition adjuvant to radiation therapy. Cancer Biother. Radiopharm. 32, 9\u201315 (2017).","journal-title":"Cancer Biother. Radiopharm."},{"key":"17460_CR41","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1172\/JCI120388","volume":"128","author":"A Thomas","year":"2018","unstructured":"Thomas, A., Murai, J. & Pommier, Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J. Clin. Invest. 128, 1727\u20131730 (2018).","journal-title":"J. Clin. Invest."},{"key":"17460_CR42","first-page":"8683","volume":"58","author":"F Zmuda","year":"2015","unstructured":"Zmuda, F., Malviya, G., Blair, A. & Boyd, M. Synthesis and evaluation of a radioiodinated tracer with specificity for poly (ADP-ribose) polymerase-1 (PARP-1) in vivo. J. Med. 58, 8683\u20138693 (2015).","journal-title":"J. Med."},{"key":"17460_CR43","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.bmcl.2017.05.077","volume":"27","author":"T Huang","year":"2017","unstructured":"Huang, T., Hu, P., Banizs, A. B. & He, J. Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma. Bioorg. Med. Chem. Lett. 27, 3472\u20133476 (2017).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"17460_CR44","first-page":"3472","volume":"27","author":"T Reiner","year":"2011","unstructured":"Reiner, T., Keliher, E. J. & Earley, S. Synthesis and in vivo imaging of a 18F-labeled PARP1 inhibitor using a chemically orthogonal scavenger-assisted high-performance method. Angew. Chem. Int. Ed. Engl. 27, 3472\u20133476 (2011).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"17460_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-017-0352-6","volume":"8","author":"JA Engelbach","year":"2018","unstructured":"Engelbach, J. A., Jannetti, S. A. & Carney, B. Discriminating radiation injury from recurrent tumor with [18 F] PARPi and amino acid PET in mouse models. EJNMMI Res. 8, 1\u201310 (2018).","journal-title":"EJNMMI Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17460-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17460-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17460-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T23:59:53Z","timestamp":1669334393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-17460-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["17460"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-17460-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.16.484613","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13034"}}